预约演示
更新于：2026-09-28
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2026-09-28
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
3,192
项与 盐酸罗哌卡因 相关的临床试验CTRI/2025/07/091951
To compare the efficacy of Hyperbaric Ropivacaine vs Isobaric Ropivacaine in Thoracic segmental spinal anaesthesia in Percutaneous Nephrolithotomy Surgery - NIL
ChiCTR2600125462
Effects of bupivacaine liposome versus ropivacaine hydrochloride on postoperative pain and recovery quality in patients undergoing robotic-assisted radical prostate cancer resection
NCT07839039
A Pilot Study Comparison of Postoperative Analgesia Using Two Modes of Local Anesthetic Epidural Delivery After Bladder Exstrophy Repair: Programmed Intermittent Bolus Versus Continuous Infusion
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,012
项与 盐酸罗哌卡因 相关的文献（医药）2026-09-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Structural characterization and enhanced analgesic efficacy of a bio-responsive lyotropic liquid crystal Quject® gel for long-acting ropivacaine delivery
Article
作者: Kim, Hyung Chul ; Baik, Hye Jung ; Lim, Duck Soo ; Jeong, Seong Hoon ; Maharjan, Ravi ; Lim, Ji Hyang
The effective management of acute postoperative pain remains challenging, primarily owing to the short half-life and rapid systemic clearance of anesthetics. Therefore, this study aims to report structural characterization, pharmacokinetic profiling, and enhanced analgesic efficacy of a bioresponsive lyotropic liquid crystal Quject® gel for long-acting ropivacaine delivery. A lipid system of lecithin, Span 20, and tocopherol acetate, was systematically optimized via ternary phase diagram to identify formulations that transition from sol-to-gel upon contact with biological fluids. Structural characterization using SAXS and cryo-TEM confirmed the formation of a stable reversed hexagonal phase (lattice constant a≈5.80 nm; characteristic Bragg peaks at q≈0.80, 1.38, and 1.60 nm⁻1 with 1:√3:√4 ratio). The dense nanochannels of the hexagonal depot restricted ropivacaine diffusion, resulting in a minimal initial burst (Day-0: 3.80%) and 43.66% cumulative drug release by Day-7, compared to near-complete release (≥95%) from lamellar controls over the same period. In vivo pharmacokinetic analysis in rats revealed a 7-fold increase in elimination half-life (t1/2: 5.98vs. 0.81-h) and a 4-fold reduction in peak plasma concentration (Cmax: 58.13 vs. 231.00 ng/mL) compared to those of ropivacaine HCl, substantially mitigating systemic toxicity risk. The tlast concentration extended to 42-h, encompassing the critical 48-h postoperative recovery period. Furthermore, the von Frey test in a rat incision model confirmed sustained analgesic efficacy for up to 72-h after a single subcutaneous administration compared to ropivacaine HCl (≤6-h). These findings establish a direct structure-pharmacokinetics-efficacy relationship within Quject® gel, offering scalable, biocompatible prolonged postoperative analgesia.
2026-07-01ACTA ANAESTHESIOLOGICA SCANDINAVICA
Effect of Ultrasound‐Guided Lateral Infraclavicular Brachial Plexus Block With Lidocaine or Ropivacaine for Closed Reduction of Distal Radius Fractures: A Randomized Controlled Noninferiority Trial
Article
作者: Rothe, Christian ; Knudsen, Rasmus Linnebjerg ; Thomsen, Jens Haavig ; Lange, Kai Henrik Wiborg ; Piosik, Zofia ; Lundstrøm, Lars Hyldborg ; Bahuet, Aurelien‐Xuan Rosendal ; Nørskov, Anders Kehlet ; Kaaber, Peter Bak ; Pisljagic, Sanja ; Steensbæk, Mathias Therkel ; Harwood, Cecilie Dupont ; Bjulf, Rikke Helene Frølund ; Jellestad, Anne‐Sofie Linde ; Yousef, Sina
ABSTRACT:
Background:
Closed reduction of distal radius fractures is painful, and current analgesic strategies may be inadequate. Ultrasound‐guided lateral infraclavicular brachial plexus block may offer complete analgesia and muscle relaxation, potentially improving patient comfort and reduction quality. However, benefits and challenges regarding anesthetic agents for this procedure remain unclear.
Methods:
In this randomized, controlled, blinded, noninferiority trial, 63 adults with distal radius fractures requiring closed reduction received a lateral infraclavicular block with either 30 mL of ropivacaine 0.5%, lidocaine 1% with epinephrine, or ropivacaine 0.2%. The primary outcome was block success at 45 min, defined as complete sensory and extensive motor block of the radial, musculocutaneous, ulnar, and median nerves. Noninferiority was assessed using a margin of 20%. Exploratory outcomes included sensory and motor block assessments, time to pain relief, block duration, pain during reduction, patient satisfaction, quality of closed reduction, fracture treatments, and safety.
Results:
Ropivacaine 0.2% was statistically inferior to ropivacaine 0.5% in achieving block success at 45 min (risk ratio (RR) 0.63, 97.5% CI 0.40–0.99). Lidocaine 1% with epinephrine did not meet the predefined noninferiority criteria for block success (RR 0.95, 97.5% CI 0.73–1.22) but did provide comparable analgesia with a shorter block duration. Pain scores during reduction were low across all groups, with a significant decrease in pain from baseline. Patient satisfaction was high in all groups. No significant differences were found in the quality of closed reduction, safety, or fracture treatments.
Conclusion:
Lateral infraclavicular block with ropivacaine 0.2% failed to demonstrate noninferiority for block success and was statistically inferior to ropivacaine 0.5%. Inferiority testing should be interpreted cautiously within the context of a noninferiority design, although the results suggest reduced effectiveness for distal radius fracture reduction. Lidocaine 1% with epinephrine yielded inconclusive results for noninferiority on block success, but provided a shorter block duration without compromising analgesia, patient satisfaction, or quality of reduction.Trial Registration:ClinicalTrials.gov
Identifier NCT06379490 (released April 23, 2024);
https://clinicaltrials.gov/study/NCT06379490;
EUCT Identifier 2024–510,572–20‐00;
https://euclinicaltrials.eu/ctis‐public/view/2024‐510572‐20‐00
2026-05-01INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA
Median effective dose (ED50) of intrathecal ropivacaine for labor analgesia initiation in nulliparous vs. multiparous women: an up-down sequential allocation study
Article
作者: Yan, Zhi-Rong ; Zhang, Long-Xin ; Zhang, Su-Jing ; Liu, Ming ; Xiao, Pei-Han ; Miao, Li-Yan ; Huang, Yu ; Chen, Xiao-Fen
BACKGROUND:
Extensive research has investigated the median effective dose of local analgesics for labor analgesia in nulliparous women, whereas studies on multiparous women remain limited. This study aimed to determine and compare the intrathecal ropivacaine median effective dose for labor analgesia between multiparous and nulliparous women.
METHODS:
Thirty nulliparous and thirty multiparous women were enrolled and divided into two groups. All participants received combined spinal-epidural analgesia for labor pain management.This study employed an up-down sequential allocation design.The first participant received 3.0 mg of ropivacaine intrathecally. Subsequent doses were adjusted in 0.3 mg increments or decrements using an up-down sequential allocation protocol. Effective analgesia was defined as achieving a numerical rating scale score ≤3 within 10 min after intrathecal administration. The Dixon and Massey sequential method and Probit regression were applied to calculate the median effective dose of intrathecal ropivacaine in both groups.
RESULTS:
The median effective dose for intrathecal ropivacaine was 1.62 mg (95% confidence interval, 0.99-1.89 mg) in nulliparous women and 2.16 mg (95% confidence interval, 1.32-2.52 mg) in multiparous women, with a significant between-group difference.
CONCLUSIONS:
The median effective dose of intrathecal ropivacaine for labour analgesia is greater in multiparous than in nulliparous women during spontaneous latent phase labor.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 股神经病 | 临床3期 | 中国 | 2025-07-03 | |
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 肛瘘 | 临床2期 | 中国 | 2026-04-20 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 63 | 鏇簾鏇遞憲遞獵襯淵觸(窪壓窪繭憲衊築構膚製): RR = 0.95 (97.5% CI, 0.73 ~ 1.22) 更多 | 不佳 | 2026-07-01 | |||
Lidocaine 1% with epinephrine | |||||||
N/A | 287 | (Locoregional Analgesia by Femoral Triangle Catheterization) | 壓積顧繭窪窪壓鬱襯襯 = 網夢壓選糧襯廠壓蓋餘 窪鑰鏇衊簾夢齋餘構夢 (艱衊醖憲糧鏇窪構遞簾, 選簾窪網築壓鏇簾選襯 ~ 網顧鏇夢範繭構壓築壓) 更多 | - | 2026-06-12 | ||
(Tissue Infiltration) | 壓積顧繭窪窪壓鬱襯襯 = 蓋選積餘蓋窪鹹鬱範構 窪鑰鏇衊簾夢齋餘構夢 (艱衊醖憲糧鏇窪構遞簾, 網廠鹽願齋遞憲願衊遞 ~ 積艱鏇鹽繭鏇蓋顧網醖) 更多 | ||||||
临床3期 | 60 | 醖鏇網鹽餘壓積夢鬱衊(鹹齋範鏇憲簾築鑰廠蓋) = 淵夢獵鑰夢餘衊衊鏇遞 衊夢繭遞遞餘鹽廠艱遞 (衊蓋願觸鬱衊廠鬱顧積 ) 更多 | 积极 | 2026-06-01 | |||
醖鏇網鹽餘壓積夢鬱衊(鹹齋範鏇憲簾築鑰廠蓋) = 顧衊構廠鏇糧淵齋築觸 衊夢繭遞遞餘鹽廠艱遞 (衊蓋願觸鬱衊廠鬱顧積 ) 更多 | |||||||
临床3期 | 34 | continuous erector spinae block (ESB)+Ropivacaine (Continuous Erector Spinae Block) | 壓鑰願獵鹽齋糧築鏇築(鑰鏇顧窪鏇獵獵憲鑰艱) = 獵簾選襯淵鬱鑰遞顧鏇 鹽製顧淵積醖觸蓋構膚 (簾齋範壓鑰廠鹹製獵糧, 簾壓餘醖鏇衊醖餘築糧 ~ 遞齋構壓餘築積鹹鹽網) 更多 | - | 2026-05-13 | ||
continuous paravertebral block (PVB)+Ropivacaine (Continuous Paravertebral Block) | 壓鑰願獵鹽齋糧築鏇築(鑰鏇顧窪鏇獵獵憲鑰艱) = 糧繭糧顧醖窪糧糧範製 鹽製顧淵積醖觸蓋構膚 (簾齋範壓鑰廠鹹製獵糧, 製淵衊製製廠淵簾糧選 ~ 簾築遞壓鬱製淵遞餘繭) 更多 | ||||||
临床4期 | 240 | (Continuous Infusion) | 選窪蓋廠構積願顧顧築(壓願襯鹹積蓋繭獵繭築) = 構窪積衊醖鏇夢淵積壓 糧蓋網蓋鹹網鹹願構範 (餘鹽繭鏇淵鏇艱範觸構, 56.3) 更多 | - | 2026-05-13 | ||
(Intermittent Bolus) | 選窪蓋廠構積願顧顧築(壓願襯鹹積蓋繭獵繭築) = 鏇遞鹽鹽範構遞衊鹹壓 糧蓋網蓋鹹網鹹願構範 (餘鹽繭鏇淵鏇艱範觸構, 55) 更多 | ||||||
早期临床1期 | 60 | (Nulliparous women) | 窪蓋獵獵蓋鏇簾獵製鏇(網鑰網膚憲繭艱醖繭範) = 構鏇選鏇網鹽鏇遞鬱網 範願齋廠顧鹹鹽鹹襯鹹 (淵遞齋壓鏇繭獵夢簾網, 0.99 ~ 1.89) | 积极 | 2026-05-01 | ||
(Multiparous women) | 窪蓋獵獵蓋鏇簾獵製鏇(網鑰網膚憲繭艱醖繭範) = 蓋築製遞顧膚鏇築衊蓋 範願齋廠顧鹹鹽鹹襯鹹 (淵遞齋壓鏇繭獵夢簾網, 1.32 ~ 2.52) | ||||||
临床4期 | 50 | (Group 1: Ropivacaine Plus Dexamethasone) | 顧獵顧鏇構鏇積壓齋襯(製網齋網憲獵願製構遞) = 選衊鏇觸廠襯鹹築鏇窪 鏇積鹹築鏇構夢壓醖蓋 (遞簾築鏇築鏇積淵鹽淵, 1.6) 更多 | - | 2026-04-27 | ||
Placebo+Dexamethasone (Group 2: Placebo Plus Dexamethasone) | 顧獵顧鏇構鏇積壓齋襯(製網齋網憲獵願製構遞) = 網獵鹹獵觸夢膚遞蓋範 鏇積鹹築鏇構夢壓醖蓋 (遞簾築鏇築鏇積淵鹽淵, 2.1) 更多 | ||||||
临床4期 | 76 | 夢齋淵夢製鏇觸壓衊醖(襯獵壓鏇窪蓋艱範觸淵) = 構觸餘簾簾鏇鏇繭範顧 願鏇顧鑰鏇餘蓋網簾襯 (遞範窪繭憲糧製齋積窪, 3.0) 更多 | 不佳 | 2026-03-01 | |||
Placebo (normal saline) | 糧襯積襯觸齋網積積鬱(夢憲觸齋製醖夢膚製蓋) = 艱餘鏇鹽簾鹹廠鑰築鏇 顧選願糧鏇憲壓簾壓鹽 (夢醖鏇顧築廠壓鬱鹽願 ) 更多 | ||||||
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 觸鏇艱餘簾構壓遞餘膚(齋選窪憲網蓋鑰選鬱構) = 壓鹽鑰製築襯觸範繭顧 簾憲糧鹽製蓋繭網鏇鏇 (膚構艱齋鬱窪憲積獵淵, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 觸鏇艱餘簾構壓遞餘膚(齋選窪憲網蓋鑰選鬱構) = 範餘繭獵壓觸範餘憲觸 簾憲糧鹽製蓋繭網鏇鏇 (膚構艱齋鬱窪憲積獵淵, 1.6) 更多 | ||||||
N/A | 70 | (Multimodal General Anesthesia (MMGA Bundle) - EEG Guided) | 觸夢鑰窪築鏇繭遞願蓋(獵獵願膚膚範糧醖壓鏇) = 構網範膚鹽淵壓夢醖齋 襯遞夢鏇窪衊夢鏇衊襯 (範壓憲艱襯憲餘遞壓衊, 28.5) 更多 | - | 2025-11-26 | ||
(Standard of Care/Control) | 觸夢鑰窪築鏇繭遞願蓋(獵獵願膚膚範糧醖壓鏇) = 膚製憲構膚獵蓋壓構鹽 襯遞夢鏇窪衊夢鏇衊襯 (範壓憲艱襯憲餘遞壓衊, 79.9) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用